文献速递认知障碍与痴呆

人类血液代谢组与阿尔茨海默病风险之间的关联

Association between Human Blood Metabolome and the Risk of Alzheimer's Disease.
PubMed 文献 · Ann Neurol · 2022-08-15

研究基于3项代谢组全基因组关联研究(GWAS)的119种独特血液代谢物(147,827名欧洲参与者),以及国际阿尔茨海默病基因组学项目63,926名欧洲个体的AD GWAS汇总数据,采用孟德尔随机化(MR)分析评估血液代谢物与AD的关联。结果鉴定出4种代谢物为AD的因果中介:硫酸表雄酮、5α-雄甾烷-3β-17β-二醇二硫酸盐、鞘磷脂和谷氨酰胺。全表型MR分析显示谷氨酰胺对4种疾病风险有益,可能是预防和治疗AD的有前景靶点且无预测的不良副作用。

要点

  • 遗传预测的硫酸表雄酮、5α-雄甾烷-3β-17β-二醇二硫酸盐和谷氨酰胺升高与AD风险降低相关。
  • 遗传预测的鞘磷脂升高与AD风险增加相关。
  • 谷氨酰胺可能是有前景的AD防治靶点,且无预测的不良副作用。

核心结论

  • 遗传预测的硫酸表雄酮、5α-雄甾烷-3β-17β-二醇二硫酸盐和谷氨酰胺升高可能与AD风险降低相关,而鞘磷脂与AD风险增加相关。
  • 谷氨酰胺可能是预防和治疗AD的有前景靶点,且无预测的不良副作用。

研究设计与样本

  • 从3项代谢组全基因组关联研究(GWAS)中选取119种独特血液代谢物,纳入147,827名欧洲参与者。
  • AD汇总数据来自国际阿尔茨海默病基因组学项目的GWAS荟萃分析,纳入63,926名欧洲个体。
  • 采用孟德尔随机化(MR)分析评估血液代谢物与AD的关联,并进一步应用全表型MR分析确定代谢物干预的潜在靶点副作用。

主要发现

  • 硫酸表雄酮每SD增加OR 0.60(95%CI 0.51-0.71;p=6.14×10^-9)。
  • 5α-雄甾烷-3β-17β-二醇二硫酸盐每SD增加OR 0.69(95%CI 0.57-0.84;p=1.98×10^-4)。
  • 鞘磷脂每SD增加OR 2.53(95%CI 1.78-3.59;p=2.10×10^-7)。
  • 谷氨酰胺每SD增加OR 0.83(95%CI 0.77-0.89;p=2.09×10^-6)。
  • 全表型MR分析显示硫酸表雄酮、5α-雄甾烷-3β-17β-二醇二硫酸盐和鞘磷脂介导多种疾病风险,谷氨酰胺对4种疾病风险有益。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Alzheimer's disease (AD) is the most common degenerative neurological disorder with limited therapeutic options. Therefore, it is particularly important to explore the potential biomarkers implicated in the occurrence and progression of AD prior to clinical testing. METHODS: We selected 119 unique blood metabolites from 3 metabolome genome-wide association studies (GWASs) with 147,827 European participants. Summary data about AD were obtained from a GWAS meta-analysis with 63,926 European individuals from the International Genomics of Alzheimer's Project. MR analyses were performed to assess the associations of blood metabolites with AD, and a phenome-wide MR analysis was further applied to ascertain the potential on-target side effects of metabolite interventions. RESULTS: Four metabolites were identified as causal mediators for AD, including epiandrosterone sulfate (odds ratio [OR] per SD increase: 0.60; 95% confidence interval [CI]: 0.51-0.71; p = 6.14 × 10-9 ), 5alpha-androstan-3beta-17beta-diol disulfate (OR per SD increase: 0.69; 95% CI: 0.57-0.84; p = 1.98 × 10-4 ), sphingomyelin (OR per SD increase: 2.53; 95% CI: 1.78-3.59; p = 2.10 × 10-7 ), and glutamine (OR per SD increase: 0.83; 95% CI: 0.77-0.89; p = 2.09 × 10-6 ). Phenome-wide MR analysis showed that epiandrosterone sulfate, 5alpha-androstan-3beta-17beta-diol disulfate and sphingomyelin mediated the risk of multiple diseases, and glutamine had beneficial effects on the risk of 4 diseases. INTERPRETATION: Genetically predicted increased epiandrosterone sulfate, 5alpha-androstan-3beta-17beta-diol disulfate, and glutamine might be associated with a decreased risk of AD, while sphingomyelin was associated with an increased risk. Side-effect profiles were characterized to help inform drug target prioritization, and glutamine might be a promising target for the prevention and treatment of AD with no predicted detrimental side effects. ANN NEUROL 2022;92:756-767.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Sun L, Guo D, Jia Y, et al. Association between Human Blood Metabolome and the Risk of Alzheimer's Disease. Ann Neurol. 2022. PMID: 35899678. doi:10.1002/ana.26464

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。